Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA2 | P00918 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22521201 | 0.97 | CA1 (0.47) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL30961785 | 0.88 | CA1 (0.47) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL22501375 | 0.87 | ALDH1A1 (0.51) | CA2ALDH1A1ALPLALPIALPG | |
| SCHEMBL22520879 | 0.85 | CA1 (0.54) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL30371850 | 0.84 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL29393066 | 0.83 | SLC9A3 (0.47) | ALDH1A1ALPLALPIALPGSLC9A3 | |
| SCHEMBL29670422 | 0.82 | MAPK1 (0.48) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL3228310 | 0.82 | CA2 (0.49) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL15570246 | 0.82 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL15570395 | 0.82 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466809-B2 | CDK2/5 degraders and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3947368-B1 | BIFUNCTIONAL COMPOUNDS COMPRISING A CDK2/5 LIGAND, A LINKER AND A E3 UBIQUITIN LIGASE BINDING DEGRON FOR THE TREATMENT OF CANCER | DANA FARBER CANCER INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466809-B2 | CDK2/5 degraders and uses thereof | CDK2, CDK5, CDK5R1 | CA1 3862/4885CA2 3900/4885CA12 4158/4885 |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | CA1 3862/4885CA2 3900/4885CA12 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.